Last reviewed · How we verify
Methylprednisone
Methylprednisone is a Small molecule drug developed by Dana-Farber Cancer Institute. It is currently in Phase 2 development. Also known as: Medrol, Depo-Medrol, Solu-Medrol, Urbason®.
Methylprednisolone is a small molecule used in the treatment of various conditions, including kidney transplantation, primary focal segmental glomerulosclerosis, myelodysplastic syndrome, aplastic anemia, and renal transplanted recipients. It is not directly mentioned as an intervention in the provided ClinicalTrials.gov data, but it is a type of corticosteroid, which is often used in conjunction with other medications such as mycophenolate mofetil in clinical trials.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Methylprednisone |
|---|---|
| Also known as | Medrol, Depo-Medrol, Solu-Medrol, Urbason® |
| Sponsor | Dana-Farber Cancer Institute |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- CORTISHOCK-P: Trial of Corticosteroids in Inflammation-Enriched Heart Failure Cardiogenic Shock (PHASE2)
- Glucocorticoids Versus Placebo for the Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis (PHASE3)
- hUC Mesenchymal Stem Cells (19#iSCLife®-LC) in the Treatment of Decompensated Hepatitis b Cirrhosishepatitis b Cirrhosis (PHASE1)
- A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients (PHASE2)
- Mycophenolate Mofetil in Patients With Progressive Idiopathic Membranous Nephropathy (PHASE3)
- ALL Adult Consortium Trial: Adult ALL Trial (PHASE2)
- Study to Assess the Efficacy and Safety of Bleselumab in Preventing the Recurrence of Focal Segmental Glomerulosclerosis in de Novo Kidney Transplant Recipients (PHASE2)
- Fecal Microbiota Transplantation With Ruxolitinib and Steroids as an Upfront Treatment of Severe Acute Intestinal GVHD (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Methylprednisone CI brief — competitive landscape report
- Methylprednisone updates RSS · CI watch RSS
- Dana-Farber Cancer Institute portfolio CI
Frequently asked questions about Methylprednisone
What is Methylprednisone?
Who makes Methylprednisone?
Is Methylprednisone also known as anything else?
What development phase is Methylprednisone in?
What does Methylprednisone target?
Related
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Dana-Farber Cancer Institute — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: Medrol, Depo-Medrol, Solu-Medrol, Urbason®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing